Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. reports developments in genomic testing for rare disease diagnosis, with recurring updates on ExomeDx™ and GenomeDx™ testing, exome and genome test volumes, revenue growth, and full-year outlooks. The company uses GeneDx Infinity™, a rare disease genomic dataset, to support clinical interpretation, AI-enabled variant analysis, and biopharma discovery.
Company news also covers research publications and medical-meeting abstracts, health economics studies involving whole exome and whole genome sequencing, sponsored genetic testing programs for suspected rare diseases, and partnerships intended to expand access to genomic diagnosis. Updates frequently connect clinical data, sequencing technology, and rare disease patient identification with the company's precision-medicine operating model.
GeneDx (Nasdaq: WGS) will present 18 abstracts at ACMG 2026 (March 12–13), highlighting sequencing innovations, AI-supported interpretation, and real-world impacts of earlier genomic diagnosis.
Presentations showcase GeneDx Infinity (more than a million exomes and genomes), AI tools to speed variant interpretation, a 51.4% diagnostic yield from >300,000 cases, and benchmarking of advanced sequencing methods.
GeneDx (Nasdaq: WGS) said company management will present at two investor conferences in March 2026: a fireside chat at TD Cowen on March 2, 2026 at 1:50 p.m. ET and a presentation at Barclays on March 11, 2026 at 3:00 p.m. ET.
Live and archived webcasts will be available in the Events section of the GeneDx investor relations website.
GeneDx (Nasdaq: WGS) reported Q4 2025 revenue of $121.0M (27% YoY; 37% ex-adjustment) and full-year 2025 revenue of $427.5M (41% YoY). Exome/genome revenue grew 32% in Q4 to $104.0M; volume rose 34% in Q4 to 27,761 results.
Adjusted gross margin was 71% in Q4 and full-year 2025. Adjusted net income was $4.4M in Q4 and $41.8M for FY2025. GeneDx reaffirmed 2026 guidance: $540–$555M revenue and 33–35% exome/genome growth.
Summary not available.
GeneDx (Nasdaq: WGS) announced that CEO Katherine Stueland was named to the TIME100 Health 2026 list, highlighting GeneDx’s role in rare disease genomics and precision medicine.
Key milestones cited include FDA Breakthrough Device designation for exome/genome testing, AAP guidance updating exome/genome as a first-tier test, and a 3.7% newborn screen positive rate in the GUARDIAN study.
GeneDx (Nasdaq: WGS) will release fourth-quarter 2025 financial results before market open on Monday, February 23, 2026.
Management will host a conference call at 8:30 a.m. Eastern Time that day to discuss financial and operating results. Registration is required; a live and archived webcast will be available on the GeneDx investor relations "Events" page.
GeneDx (Nasdaq: WGS) reported preliminary, unaudited results for 2025 and issued 2026 guidance. Management expects 2025 revenue of $427M (+41% YoY) and exome & genome revenue of $360M (+54% YoY). Exome & genome volume rose to 97,271 results (+30.5%) with Q4 volume growth accelerating to 34.3%. full-year adjusted gross margin is ~71% and Q4 adjusted gross margin ~71%. Cash and equivalents were about $172M at year-end. For 2026 the company guides $540–$555M revenue, 33–35% exome & genome revenue and volume growth, adjusted gross margin at least 70%, and positive adjusted net income. Results remain subject to audit and adjustment.
GeneDx (Nasdaq: WGS) announced a strategic partnership with Komodo Health to link GeneDx Infinity’s rare disease genomic and phenotypic dataset with Komodo’s Healthcare Map®, creating a longitudinal rare disease dataset. The combined resource connects >2.5 million genetic tests, >7 million phenotypic data points, and Komodo’s view of >330 million de-identified patient journeys to support HEOR, R&D, clinical trial cohort ID, market access, and AI model training.
GeneDx reports Infinity produced 30% more exome/genome data in 2025 than the prior 24 years combined and includes nearly 1 million exomes/genomes and ~1 million uniquely classified variants.
GeneDx (Nasdaq: WGS) announced GenomeDx Prenatal, a phenotype-informed, trio whole genome sequencing test for pregnancies with fetal anomalies, available to order in February 2026. The test builds on >10 years of prenatal experience and >4,000 prenatal exomes, uses the GeneDx Infinity rare-disease dataset, and targets broad variant detection across key prenatal indications with results in less than two weeks. GenomeDx Prenatal is positioned to inform time-sensitive counseling, delivery planning, and postnatal care through comprehensive detection, free postnatal reanalysis, and optional lifetime reanalysis.
GeneDx (Nasdaq: WGS) appointed Dr. Linda Genen, MD, MPH as Chief Medical Officer on January 6, 2026 to lead Medical and Clinical Affairs and drive clinical strategy for earlier diagnosis and broader adoption of genomic medicine.
Dr. Genen joins from ProgenyHealth and has prior leadership at UnitedHealth Group, Optum, and clinical experience as a neonatologist and assistant professor. She will guide payer engagement, real-world evidence initiatives, and cross‑functional innovation to expand exome and genome testing in routine care.